Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART

AIDS

Volumn 20, Issue 13, 2006, Pages 1727-1736

  Marchetti, Giulia ^a   Gori, Andrea ^a   Casabianca, Anna ^b   Magnani, Mauro ^b   Franzetti, Fabio ^a   Clerici, Mario ^c   Perno, Carlo Federico ^d   Monforte, Antonella D'Arminio ^a   Galli, Massimo ^a   Meroni, Luca ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Discordant patients; HAART; T cell activation; T cell homeostasis; T cell proliferation

Indexed keywords

CD38 ANTIGEN; INTERLEUKIN 7; KI 67 ANTIGEN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; T LYMPHOCYTE RECEPTOR; VIRUS DNA; VIRUS RNA;

ADULT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; T LYMPHOCYTE ACTIVATION; THYMUS; TURNOVER TIME;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; APOPTOSIS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; DNA, VIRAL; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INTERLEUKIN-7; KI-67 ANTIGEN; MALE; MIDDLE AGED; THYMUS GLAND;

EID: 33748052966     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000242819.72839.db     Document Type: Article

References (43)

1. Autran B, Carcelain G, Li TS, Gorochov G, Blanc C, Renaud M, et al. Restoration of the immune system with anti-retroviral therapy. Immunol Lett 1999; 66:207-211.
2. Piketty C, Castiel P, Belec L, Batisse D, Mohamed A, Gilquin J, et al. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 1998; 12:745-750.
3. Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pedron B, et al. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005; 191:1670-1679.
4. Lederman HM, Williams PL, Wu JW, Evans TG, Cohn SE, McCutchan JA, et al. Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis 2003; 188:1794-1803.
5. Meroni L, Marchetti G, Gatti N, Monforte A, Galli M. Delayed-type hypersensitivity skin testing can predict CD4 count increase in HIV patients with poor immunologic response to HAART. J Acquir Immune Defic Syndr 2003; 33:277-278.
6. Paiardini M, Cervasi B, Galati D, Dominici S, Albrecht H, Sfacteria A, et al. Early correction of cell cycle perturbations predicts the immunological response to therapy in HIV-infected patients. AIDS 2004; 18:393-402.
7. d'Arminio Monforte A, Testori V, Adorni F, Castelnuovo B, Bini T, Testa L, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS 1999; 13:1669-1676.
8. Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-2195.
9. Pitrak D, Bolanos J, Hershow R, Novak R. Discordant CD4 T lymphocyte responses to antiretroviral therapy for HIV infection are associated with ex-vivo rates of apoptosis. AIDS 2001; 115:1317-1319.
10. Garcia F, Vidal C, Plana M, Cruceta A, Gallart M, Pumarola T, et al. Residual low-level viral replication could explain discrepancies between viral load and CD4+ cell response in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clin Infect Dis 2000; 30:392-394.
11. Chun T-W, Shawn Justement J, Pandya P, Hallahan C, McLaughlin M, Liu S, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis 2002; 185:1672-1676.
12. Teixeira L, Valdez H, McCune J, Koup R, Badley A, Hellerstein M, et al. Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-1756.
13. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-1543.
14. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33:125-133.
15. Douek DC. Disrupting T-cell homeostasis: how HIV-1 infection causes disease. AIDS Rev 2003; 5:172-177.
16. Zehender G, Varchetta S, De Maddalena C, Colasante C, Riva A, Meroni L, et al. Resistance to Fas-mediated apoptosis of human T-cell lines expressing human T-lymphotropic virus type-2 (HTLV-2) Tax protein. Virology 2001; 281:43-50.
17. Al-Harthi L, Marchetti G, Steffens C, Poulin J, Sekaly R, Landay A. Detection of T cell receptor circles (TRECs) as biomarkers for de novo T cell synthesis using a quantitative polymerase chain reaction-enzyme linked immunosorbent assay (PCR-ELISA). J Immunol Methods 2000; 237:187-197.
18. Casabianca A, Orlandi C, Fraternale A, Magnani M. Development of a real-time PCR assay using SYBR Green I for provirus load quantification in a murine model of AIDS. J Clin Microbiol 2004; 42:4361-4364.
19. Casabianca A, Orlandi C, Fraternale A, Magnani M. A new onestep RT-PCR method for virus quantitation in murine AIDS. J Virol Methods 2003; 110:81-90.
20. Sieber PD. Quantitative RT-PCR. In: Quantitative PCR protocols. Edited by Reischl BKaU. Totowa, New Jersey: Humana Press; 1999:65-67.
21. Schwarting R, Gerdes J, Niehus J, Jaeschke L, Stein H. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods 1986; 90:65-70.
22. Kovacs J, Vogel S, Metcalf J, Baseler M, Stevens R, Adelsberger J, et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001; 31:1351-1360.
23. Mohri H, Perelson AS, Tung K, Ribeiro RM, Ramratnam B, Markowitz M, et al. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med 2001; 194:1277-1287.
24. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 2003; 17:1881-1888.
25. Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, et al. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 2004; 18: 211-216.
26. Borkow G, Leng Q, Weisman Z, Stein M, Galai N, Kalinkovich A, et al. Chronic immune activation associated with intestinal helminth infections results in impaired signal transduction and anergy. J Clin Invest 2000; 106:1053-1060.
27. Homann D, Teyton L, Oldstone M. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med 2001; 7:913-919.
28. Gougeon ML, Lecoeur H, Dulioust A, Enouf MG, Crouvoiser M, Goujard C, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996; 156:3509-3520.
29. Ribeiro R, Mohri H, Ho D, Perelson A. In vivo dynamics of T cell activation, proliferation and death in HIV-1 infection: why are CD4+ but not CD8+ T cells depleted? Proc Natl Acad Sci USA 2002; 99:15572-15577.
30. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS 1996; 10:827-834.
31. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry 1996; 26:1-7.
32. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
33. Nobile M, Correa R, Borghans JA, D'Agostino C, Schneider P, De Boer RJ, et al. De novo T-cell generation in patients at different ages and stages of HIV-1 disease. Blood 2004; 104:470-477.
34. Napolitano L, Grant R, Deeks S, Schmidt D, De Rosa S, Herzenberg L, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001; 7:73-79.
35. Fry T, Mackall C. Interleukin-7: master regulator of peripheral T-cell homeostasis? TRENDS Immunol 2001; 22:564-571.
36. Zaunders J, Cunningham P, Kelleher A, Kaufmann G, Jaramillo A, Wright R, et al. Potent antiretroviral therapy of primary human immunodeficiency virus type-1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia. J Infect Dis 1999; 180:320-329.
37. Baldanti F, Paolucci S, Gulminetti R, Maserati R, Migliorino G, Pan A, et al. Higher levels of HIV DNA in memory and naive CD4(+) T cell subsets of viremic compared to non-viremic patients after 18 and 24 months of HAART. Antiviral Res 2001; 50:197-206.
38. Ostrowski SR, Katzenstein TL, Thim PT, Pedersen BK, Gerstoft J, Ullum H. Low-level viremia and proviral DNA impede immune reconstitution in HIV-1-infected patients receiving highly active antiretroviral therapy. J Infect Dis 2005; 191:348-357.
39. Havlir DV, Strain MC, Clerici M, Ignacio C, Trabattoni D, Ferrante P, et al. Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol 2003; 77:11212-11219.
40. Smith D, Zaunders J, Kauffman G, CunninghamP, Grey P, Goh L, et al. Greater suppression of CD8 activation with 4 vs 3 drugs in early stages of primary HIV infection (PHI) despite similar virological decay rates. First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, July 2001 [abstract 61].
41. Fumero E, Garcia F, Gatell JM. Immunosuppressive drugs as an adjuvant to HIV treatment. J Antimicrob Chemother 2004; 53:415-417.
42. Arnò A, Ruiz L, Juan M, Jou A, Balague M, Zayat MK, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with ≤ 250/microL CD4 T cells and undetectable plasma virus load. J Infect Dis 1999; 180:56-60.
43. Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, et al. Low-dose prolonged intemittent Interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency-virus positive patients with advanced immune impairment. J Infect Dis 2002; 186:606-616.